Osteosarcoma

These findings reveal that geniposide inhibits osteosarcoma through dual mechanisms: Ndufs8-mediated oxidative phosphorylation activation and PD-L1/PD-L1 axis suppression, offering a novel therapeutic strategy. These findings suggest that geniposide is a promising therapeutic agent for osteosarcoma and may enhance the efficacy of immunotherapy combined with PD-L1 blockade.

Mechanistically, the viral non-structural protein NSP2 disrupts super-enhancer activity by recruiting the CUL2-RBX1-ELOC complex, which triggers K63-linked ubiquitination and degradation of RPB1. Together, these findings uncover a previously unrecognized mechanism underlying M1 activity in osteosarcoma, support further preclinical evaluation of M1 in this setting, and identify RPB1 as a candidate biomarker for virotherapy response.

P1, N=27, Not yet recruiting, Baylor College of Medicine | Initiation date: May 2026 --> Aug 2026

MT in denosumab-treated GCTB is rare and does not appear more frequent than historical baseline rates, but it predominantly affects a biologically and clinically high-risk subgroup. Vigilant clinical and radiological surveillance, prompt re-biopsy of atypical lesions, and referral to expert sarcoma centers are essential, and prospective registries with integrated molecular profiling are urgently needed.

We present a unique case of primary pelvic extraskeletal Ewing sarcoma in a previously healthy young woman with localized invasion into the uterus, vagina, and bladder. Given the rarity of this disease, paucity of data, and potential for misdiagnosis, clinicians must maintain high suspicion for pelvic extraskeletal Ewing sarcoma.

PTHR1 promotes OS progression by activating the CREB1/PVT1/miR-590-3p/AXIN2 regulatory axis and enhancing EMT. This five-component signaling cascade may provide potential biomarkers and therapeutic targets for OS.

Using genomics as the benchmark, OFD-like adamantinomas might be better delineated by light microscopy or p40 than by cytokeratin immunohistochemistry. These data expanded our molecular understanding of these rare bone tumors.

In vitro assays confirmed that TGFA knockdown suppresses OS cell proliferation and migration while increasing apoptosis, whereas TGFA overexpression promotes these malignant behaviors. By bridging dietary polyphenol research with oncogenic management, this study identifies the TGFA-associated immune axis as a precise molecular roadmap for the structural modification of polyphenols and the design of target-specific, tannin-based functional foods for chronic disease intervention.

P1, N=12, Terminated, National Cancer Institute (NCI) | Completed --> Terminated; Drug supply issues

The results suggest that DRG score can serve as an effective prognostic indicator for cancer patient survival and have specific implications in osteosarcoma. In the future, DRG-based scoring systems may serve as novel biomarkers and therapeutic targets.

These two cases expand on the known histologic and molecular spectrum of uterine mesenchymal neoplasms with tyrosine kinase receptor gene fusions. Recognition of these entities is important for appropriate classification, prognostication, and identification of patients eligible for targeted therapies such as TRK or FGFR inhibitors.

Compared to the reference drug 5-fluorouracil (5-FU), several compounds displayed notable antiproliferative activity...Among these, compounds 4 and 10 exhibited the most favorable anticancer profiles, combining potent antiproliferative activity with minimal toxicity to normal cells. Furthermore, to support the experimental anticancer findings, in silico molecular docking studies were performed using the crystal structures of caspase-3 (1GFW), human metalloproteinase-13 (3KEJ), human estrogen receptor (3ERT), and EGFR (1M17) against compounds 1, 2, 4, and 10, and their binding modes were analyzed.